Image via Wikipedia
SAN FRANCISCO, CA — (Marketwire) — 07/23/09 — Cannabis Science Inc. (OTCBB: CBIS), an emerging pharmaceutical cannabis company, is pleased that today’s Wall Street Journal article on the booming medical cannabis industry in California notes the role of Cannabis Science Inc.
Commenting on why Cannabis Science was mentioned in the article, Richard Cowan, chief financial officer of Cannabis Science Inc., said, “Although the company is beginning the FDA approval process for its products, we believe that the inclusion of Cannabis Science Inc. in an article about the struggle to get medical cannabis to patients is further evidence that we are a patient oriented company, whose business strategy does not depend on a continuation of marijuana prohibition.”
Although the company is not involved in the state’s gray market, the article notes, “A pot activist named Richard Cowan has opened what he envisions as an investment bank for pot-related businesses, called General Marijuana (General Marijuana.com). Mr. Cowan is also chief financial officer of Cannabis Science Inc., which is trying to market a pot lozenge for nonsmokers.” Please click http://online.wsj.com/article/SB124829403893673335.html to read the article in full.
Image via WikipediaCannabis Science CEO, Dr. Robert J. Melamede, observed, “This article is further demonstration of the huge need for FDA approved medical cannabis products.”
Earlier this week, Cannabis Science reported that Dr. Melamede had spoken at a hearing in Denver in opposition to an attempt to undermine a voter-approved constitutional amendment that would have made it much more difficult for patients to get affordable medical marijuana.
Cannabis Science Inc. is at the forefront of medical marijuana research and development. The company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. It is dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.